Trial Profile

A study of TNAX 101A for ulcerative colitis

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antifibrotics (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use

Most Recent Events

25 Aug 2025 New trial record
29 Jul 2025 According to Formation Bio media release, the company announced that Formation Bio has licensed worldwide rights to TNAX 101A. The clinical program, which has received IND clearance, will be advanced by Formation Bio in autoimmune indications, initially ulcerative colitis.
29 Jul 2025 According to Formation Bio media release, this study has received IND clearance.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com